

Breast Cancer

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Trial Status
Recruiting

Trial Runs In
8 Countries

Trial Identifier
NCT06274515 WO44977

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT06274515 WO44977
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
